The stock's rise snapped a five-day losing streak.

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...

The 69-year-old actor opened up about his harrowing experience which took place during the pandemic on Joe Rogan's podcast.

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

Actor Mel Gibson recently opened up about a challenging chapter in his life, sharing details of his battle with COVID-19 and ...

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth r ...